A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy without Disease Recurrence

We are doing this study to learn more about an experimental drug called Camizestrant. Experimental means it hasn't been fully tested and it is not approved by any health authority, including the FDA, except for use in research studies like this. We want to see if extended therapy with Camizestrant is better at preventing disease recurrence (disease that comes back) than continuation of standard endocrine therapy (Letrozole, Anastrozole, Exemestane, or Tamoxifen, the drugs that you and other patients with early ER+/HER2- breast cancer are currently receiving). We also want to better understand the studied disease and associated health problems.